BTEC:SW:SW-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD (USD)

ETF | Others |

Last Closing

USD 6.786

Change

+0.04 (+0.53)%

Market Cap

N/A

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

-0.04 (-0.31%)

USD 1,244,681.59B
XNIF:SW Xtrackers Nifty 50 Swap UCITS ..

-3.40 (-1.41%)

USD 292,109.69B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

-0.15 (-0.72%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

-0.30 (-1.09%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

+2.00 (+0.02%)

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

-21.00 (-0.38%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

-3.80 (-0.22%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

-21.50 (-0.95%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

-0.45 (-0.59%)

USD 131,872.43B

ETFs Containing BTEC:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.28% 40% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.28% 40% F 45% F
Trailing 12 Months  
Capital Gain 20.58% 68% D+ 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.58% 68% D+ 70% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.97% 56% F 57% F
Dividend Return 4.97% 56% F 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.57% 53% F 58% F
Risk Adjusted Return 65.65% 52% F 57% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike